Accès ouvert
2025
article
OpenAlex
Obbina Abani, Amr E. Abbas, Fatima Abbas, Kaja Abbas et autres
BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital …
Accès ouvert
2025
article
OpenAlex
Obbina Abani, Amr E. Abbas, Fatima Abbas, Jonathan R. Abbas et autres
BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia, for whom data on these antivirals are scarce. METHODS: The RECOVERY …
2025
article
OpenAlex
Gemma Taylor, László Romics, Julie Doughty, James Mansell et autres
gb
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Mhairi Mactier, Laura Arthur, Joanne Edwards, Julie Doughty et autres
Background: Post-operative complications (POCs) affect 36.1% of breast cancer patients. POCs are associated with inferior oncological outcomes in gastro-intestinal, lung, and head and neck cancers. Evidence is less clear in breast cancer. The James Lind Alliance demonstrated the importance of exploring risk …
gb
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Mhairi Mactier, James Mansell, Laura Arthur, Julie Doughty et autres
BACKGROUND: Recent evidence suggests a survival advantage after breast-conserving surgery compared with mastectomy. Previous studies have compared survival outcomes after standard breast-conserving surgery, but no studies have compared survival outcomes after oncoplastic breast-conserving surgery. The aim of this study was to compare …
gb
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Obbina Abani, Amr E. Abbas, Fatima Abbas, Jaffar Abbas et autres
Background: Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with clinical hypoxia but not receiving ventilatory support (the combination of non-invasive …
Accès ouvert
2024
article
OpenAlex
McLean KA, Knight SR, Nina M. Clark, Adesoji Ademuyiwa et autres
Abstract Background Identification of patients at high risk of surgical-site infections may allow surgeons to minimize associated morbidity. However, there are significant concerns regarding the methodological quality and transportability of models previously developed. The aim of this study was to develop a …
gb
(code pays fourni par la source)
2024
article
OpenAlex
Katie Bennett, Rachel Morris, E. Mallon, J. Campbell et autres
gb
(code pays fourni par la source)
2024
article
OpenAlex
Samantha Ng, László Romics, Christopher J. Wilson, Julie Doughty et autres
gb
(code pays fourni par la source)
2024
article
OpenAlex
Rachel Morris, Katie Bennett, E. Mallon, J. Campbell et autres
gb
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Saul N. Faust, Richard Haynes, Christine E. Jones, Natalie Staplin et autres
BACKGROUND: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with …
us, de, gb
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Obbina Abani, Amr E. Abbas, Fatima Abbas, Jonathan R. Abbas et autres
BACKGROUND: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19. METHODS: In the randomised, controlled, …